Dyne Therapeutics is an early-stage company gearing up for its first launch, promising to tackle unmet need in patients with neuromuscular disease. President and CEO John Cox outlines the science behind the company’s ambitions, and the expansion efforts that will support its metamorphosis from early-stage company to fully-fledged biotech.

Key Points

• Dyne Therapeutics is pioneering a new delivery method for its products targeting neuromuscular disease.

• With two launches planned, the business is preparing to transform from early-stage company to fully-integrated biotech.

• Shared clinical and commercial pathways for Dyne’s primary disease areas allow for capital investment efficiencies.

• Introductions [00:06]

Host Joe Coletti introduces John Cox, President and CEO of Dyne Therapeutics, a clinical-stage biotechnology company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases.

• Dyne’s journey to commercialization [00:47]

Dyne spent 2025 validating its delivery platform. In 2026 it aims to transform itself from an early-stage to a commercial company, with its first product launch scheduled for 2027.

• Novel drug delivery method [02:09]

While most genetic therapies approved for use in the past 10 years have been delivered to the liver, Dyne’s technology is designed to deliver direct to the muscle and the central nervous system.

• Evidence of effectiveness [03:37]

The technology allows for higher-than-typical dosage, but with a favorable safety profile. Trials are showing an improvement in function from baseline for patients with Duchenne muscular dystrophy and myotonic dystrophy.

• Capabilities and capital investment [06:22]

The company is drafting in new capabilities to prepare for product launches. With $900m on the balance sheet, it is well capitalized. Its disease areas share the same clinical and commercial pathways, allowing for efficient capital allocation.